CA1140705A - Vascular prosthesis - Google Patents
Vascular prosthesisInfo
- Publication number
- CA1140705A CA1140705A CA000337441A CA337441A CA1140705A CA 1140705 A CA1140705 A CA 1140705A CA 000337441 A CA000337441 A CA 000337441A CA 337441 A CA337441 A CA 337441A CA 1140705 A CA1140705 A CA 1140705A
- Authority
- CA
- Canada
- Prior art keywords
- vascular prosthesis
- substance
- coagulant
- elastomer
- tubing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0029—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using an intermediate layer of polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
Abstract
ABSTRACT OF THE DISCLOSURE
A vascular prosthesis comprising a porous tubing of polytetrafluoroethylene containing an anti-coagulant substance and bonded to its outside surface a porous elastomer coating containing substance which counteracts the anti-coagulant sub-stance is disclosed.
A vascular prosthesis comprising a porous tubing of polytetrafluoroethylene containing an anti-coagulant substance and bonded to its outside surface a porous elastomer coating containing substance which counteracts the anti-coagulant sub-stance is disclosed.
Description
~14Q7~)5 B~CKGROUND OF TE~E IN~IENTION
1. Field of the Invention This invention relates to a vascular prosthesis composed of a porous tubing of polytetrafluoroethylene (to be abbrevia-ted "PTFE"), and aims at increasing the anti-coagulatin~ property of its inner surface, preventing bleeding, and is directed to increas-ing the strength of the tubing and improving the ability of its outside surface to connect with the tissues of a patient.
1. Field of the Invention This invention relates to a vascular prosthesis composed of a porous tubing of polytetrafluoroethylene (to be abbrevia-ted "PTFE"), and aims at increasing the anti-coagulatin~ property of its inner surface, preventing bleeding, and is directed to increas-ing the strength of the tubing and improving the ability of its outside surface to connect with the tissues of a patient.
2 Description of ~he Prior ~rt .
Many reports have been made heretofore to show that a porous tubing of PTFE produced ~y a stretching method can be clinically used as a vascular prosthesis~ Such a prosthesis is regarded as better than conventional vascular prostheses made of knitted or woven fabrics. A PTFE tubing which has been subjected to a stretching treatment has a microstructure composed of very fine fi~ers and nodes connected to one another by these fibers.
The diameters of the fibers vary depending on stretching conditions, but can be made much smaller than t~lose of the fibers of the knitted or woven fibrics mentioned above. Moreover, since the pore diameter ~ and porosity of the tubing can be varied freely, when it is used as an artificial vessel, it is pliable and scarcely permits - ormation of thrombus. The tubing also shows good formation of a neoint`ima on its inner surface without any apprecia~le adverse effect on the surrounding tissues. Thus, the stretched PTFE tubing is regarded as one of the best vascular prostheses.
However, the porous PTFE tubing of PTFE produced by stretching is not completely free from formation of thrombus and still has room for improvement. The stretched PTFE tu~ing also has the disadvantage that when it is used as a vascular prosthesis and ~oined with ~he living body, the needle or suture tends to 7C~5 1 tear the tubing. Moreover, it is difficult for natural occlusion of suture holes to occur ~ase~ on the elasticity of the porous PTFE tubing alone, and bleeding from the suture holes is sometimes noted after the junction operation. Another problem is the low ability of the outside surface of the porous PTFE tubing to connect with the surrounding tissues of a patient.
The present invention offers a solution to these problems.
SUMMAR~ OF THE INVENTION
It is an object of this invention to provide a vascular prosthesis which is free ~rom the formation of thrombus and tearing and permits natural occlusion of suture holes.
According to this invention, there is provided a vascular prosthesis comprising a porous tubing of polytetrafluoroethylene containing an anti-coagulant su~stance and bonded to its outside surface, a porous elastomer coating containing a su~stance which counteracts the anti-coagulant.
DETAILED DESCRIPTION OF THE IN~ENTION
Since the vascular prosthesis of this invention contains an anti-coagulant substance, thrombi do not form on its inside surface. The provision of the porous elastomer coating obviates the problem of tube tearing, and suture holes are occluded under the elasticity of the coating. Should bleeding occur in the sutured areas, it will be stopped by the counteracting substance contained in the coated portion. This substance can further prevent bleeding incident to the leak~age of the anti-coayulant substance.
In addition, the ability of the tubing to conne~t wlth the surround-ing tissues of a patient is increased by the porous elastomer coat-ing The porous tubing of PTFE in accordance with this invention is produced by the method described in Japanese Patent Publication s 1 No. 13560/67 and, e.g., U~S. Patents 3,962,153 and 3,953,566. A
liquid lubricant is mixed with an unsintered powder of polytetra-fluoroethylene, and the mixture is extruded into a tubular form ~y a ram-type extruder. The PTFE used in this invention preferably has a molecular weight of 106 to 107. The tubing is stretched at least monoaxially after the li~uid lu~ricant is optionally removed from it. The tubing is then heated at a temperature above about 327C which is the sintering temperature while fixing it in place to avoid shrinkage. Thus, the stretched and expanded 1~ structure is fixed to give a tubing having increased strength.
The resulting porous PTFE tubing has a microstructure composed of very fine fibers and nodes connected to one another by these fibers. Because t~e diameters and lengths o these fiber~ and the sizes and number of the nodes can be varied depending upon the stretching and sintering conditions, the pore diameter and porosity of the resulting porous tubing can be freely determined. It has been clinically confirmed that as a vascular prosthesis it suitably has an average pore diameter of about 2~m to about 100 ~m, a poroslty of at least about 70~, and a wall thickness of about 0.3 to about 1.0 mm, In a preferred form of the microstructure of the porous PTFE tubing used in this invention, the fibers are distributed not unidirectionally but radially. This fibrous structure is obtained by biaxially stretching the PTFE tubing, namely by stretching it in the axial direction and expanding its diameter.
Expansion of its diameter can be achieved by reducing the pressure on the outside surface of the tubing, or applying pressure to its inside surface, or simultaneously performing these two procedures.
Alternatively, the diameter of the tubing may ~e mechanically enlarged by passing an ar-ticle of a suitable configuration through 114()7~i 1 the inside of the tubing. Stretching of the tubing in the axial direction and expansion of its diameter are carried out simul-taneously or successively, or may be carried out simultaneously with the final sintering step. The porous PTFE tubing o~tainea by the biaxial stretching method is more pliable and less prone to longitudinal tearing than a porous PTFE tubing stretched only in the axial direction, because the fibers are distributed not only in the axial direction ~ut radially in all directions. However, for use as a vascular prosthesis, it still leaves room for improvement.
The porous elastomer coa~ing is used in this invention for the purpose of preventing tearing of the tubing, stopping ~leeding by occlusion of suture holes by the elastomer, and increasing the ability of the tubing to connect with the surrounding tissues of a patient.
Any elastomer can be used in this invention whic~ does not harm the body. Examples are fluorine ru~ber, silicone rubber, urethane rubber, acrylic rubber, and natural rubber. Usually, elastomers are used in the crosslinked state, and in this invention, ~ too, the elastomers are used preferably in the crosslinked-state in order to prevent their deterioration in the living body.
For use as a vascular prosthesis, the suitable average pore diameter of the porous elastomer coating is from about lO~m to a~out 500 ~m, a sufficient thickness of the coating is equal to, or smaller than, the wall thickness of t~e porous PTFE tubing, i.e., a~out 20~1m to about 500~m, and the elastomer has a porosity of about 50% to about ~0%.
A porous coating of the elastomer can ~e formed on the outside surface of the porous PTFE tubing by a variety of methods including a method comprising wrapping a separately prepared porous sheet of the elastomer about the outside surface of the tubing and 7C~S
1 bonding it, a method comprising coating a solution of an elastomer comp3und containing a ~lowing agent on the outside surface of the tubing and then decomposing the blowing agent, a method comprising coating a solution of an elastomer compound having a soluble substance dispersed therein on the outside surface of the tubing, and dissolving the soluble substance to form a porous structure, a method comprising dissolving an elastomer compound in a mixture of a solvent and a nonsolvent, coating the solution on the outside surface of the tubing, and dr~ing the coating to render it porous, or a method comprising coating a solution of an elastomer compound on the outside surface of the tubing, and removing the residual solvent ~y dippiny the coated tubing in a nonsolvent bath or heat-ing it to a temperature a~ove the boiling point of the solvent, thereby to render the coating porous.
In the particular, a method for forming a porous coating of an elastomer, which comprises coating the outside surface of porous tubing of PTFE with a solution of an elastomer compound or a liquid elastomer compound, and before drying the elastomer coat-ing, applying a negative pressure to the inside wall o the porous tubing with a gas or liquid whereupon passing through the elastomer the gas or liquid forms the elastomer and thus renders the coatingporous has been found to be most suitable for the o~ject of this invention. The term "negative pressure'r as used herein denotes a pressure greater on the inside wall than the outside wall of the tubing. A pressure of about 0.05 to 1 kg/cm2 is usually applied to the inside wall of the tubing. A preferred viscosity of the elastomeric coating before forming is from about 100 to about 5,000 c.p~ at 25C.
The elastomer compound, as used herein, denotes a mixture of the elastomer with a crosslinking agent, etc.
07~
1 In the resulting structure comprising the porous PTFE
tubing and the porous elastomer coating ~onded to its outside surface, the porous PTF~ tubing portion contains an ant-coagulant substance, and the porous elastomer coating contains a substance which counteracts the anti-coagulant substance.
The anti-coagulant substance serves to increase the anti-coagulating property of the inside surface of the porous PTFE tubing, and to provide an artificial vessel which shows a high patency rate without the formation of thrombus. It is provided ~ithin the pores of the porous PTFE tubing. The anti-coagulant su~stance may be provided uniformly over all the por~s of th~
porous PTFE tubing, but is preferably only on the inside surface of the tubing.
Examples of the anti-coagulant substance include polysaccharide sulfates such as heparin, its derivatives, chondroitin sulfate, charonin sulfate, and organic acids such as citric acid. Heparin sodium is most effective and is most easily availabe.
To provide the anti-coagulant substance in the pores of 29 the porous PTFE tubing, the tubing is dipped in a solution of the anti-coagulant substance and dried. Or a polymeric gel or the like is provided within the pores, and the anti-coagulating substance i5 held therein. The latter method generally gives better results with regard to the durability of the anti-coagulating property of the substance. Examples of materials for the polymeric gel include synthetic water-soluble polymers such as polyvinyl alcohol, polyethylene oxide, polyethylene glycol, polyvinyl pyrrolidone and poly acrylic acid, and natural hydrophilic polymers such as cellulose derivatives, pectin, and alginic acid.
The anti-coagulant substance may be held in the PTFE
~140q~
1 tubing by mixing it with a solution of the above polymer, impreg-nating the pores of th~ porous PTFE tubing with. the solution, and gelling the solution by a method suitable for the respective polymer (the term "gelling" includes cross-linking). Another effective method comprising impregnating the pores o-f the PTFE
tubing with a solution of a polymeric amine such as polyethyleneimine or polyvinyl-amine, crosslinking the polymer, quaternizing it, and contacting the product with a solution of heparin sodium or the like to bond heparin ionically as described in Japanese Patent tO Application (OPI) No. 13694/1979 published E`ebruary 1, 19~'~ (The term "OPI" as used herein refers to a "published unexamined Japanese patent application") corresponding to U.S. Patent Application Serial No. 921,680, filed July 3, 1978. It has already been found that ionically bonded heparin or the like has a better anti-coagulating effect than that bonded by other methods, and its effect lasts for an extended period of time. In the present invention, too, this bonding method has been found to be most effective.
When a hydrophilic polymer is used to hold the anit-coagulant substance, it results in the formation of a hydrophilic portion on the surface of PTFE which is highly waterrepellen-t, and therefore, the product also shows an anti-coagulant effect attributed to a balanced combination of water repellency and hydrophilicity. Coupled with the activity of the anti-coagulant substance, this provides a vascular prosthesis having superior properties. A suitable concentration for the polymeric solution is usually not more than 10 wt%, and the suitable concentration for the anti-coagulant substance is in the range oE about 0.2 to 5 wt~ (in the case of heparin sodium). Conveniently, impregnation is performed only on the inside surface of the porous PTFE -tubing such that the anti-coagulating property of onl.y the inside surface is increased.
1~40~7~5 1 The counteracting subs~ance for the anti-coagulant su~stance in this invention is contained in the porous elastomer coating portion, and serves to stop bleeding. The counteracting substance includes a substance which acts in a way opposite to the anti-coagulant substance on the inside surface of the tu~ing, and a su~stance which reduces or nullifies the function of the anti-coagulant. Example~ of the counteracting su~stance are inorganic or organic coagulating substances such as silica, alumina, car~on black, or activated carbon, and antagonistic agents against anti-coagulant substances. Typical examples oE antagonistic agents against heparin are protamine~ and its derivatives such as protamine sulfate and protamine zinc.
Such a counteracting substance may be incorporated into the elastomer as a filler, or provided in the pores of the porous elastomèr coating. When it is mixed with the elastomer, its amount is sufficiently up to 10% by weight based on the weight of the elastomer. When it is provided in the pores of the elastomer coating, its amount may be small. Desirably, it is used in an amount larger than that which is required to nullify the entire ~ amount of the anit-coagulant substance.
The provision of the coagulating substance in the pores of the elastomer coating is suitably achieved by impregnating the porous elastomer with a dispersion of coagu~ating substance and drying the impregnated elastomer. It has been confirmed that the coagulating substancQ present in-the pores of the elastomer will not come out. In order to fix the coagulating substance onto the inner surface of the pores a binder may be used or the part of the elastomer may be dissol~ed and resolidified to bind the coagulating su~stance.
As described in detail hereinabove, the vascular ~40~Q5 1 prosthesis of this invention is an improvement over a conventional vascular prosthesis composed mainly of a porous PTFE tubing, and also is given a high level of function, exhibiting characteristics not seen in the prior art.
While the invention has been described in detail and with reference to specific em~odiments thereof, it will be apparent ~o one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof~
_g_
Many reports have been made heretofore to show that a porous tubing of PTFE produced ~y a stretching method can be clinically used as a vascular prosthesis~ Such a prosthesis is regarded as better than conventional vascular prostheses made of knitted or woven fabrics. A PTFE tubing which has been subjected to a stretching treatment has a microstructure composed of very fine fi~ers and nodes connected to one another by these fibers.
The diameters of the fibers vary depending on stretching conditions, but can be made much smaller than t~lose of the fibers of the knitted or woven fibrics mentioned above. Moreover, since the pore diameter ~ and porosity of the tubing can be varied freely, when it is used as an artificial vessel, it is pliable and scarcely permits - ormation of thrombus. The tubing also shows good formation of a neoint`ima on its inner surface without any apprecia~le adverse effect on the surrounding tissues. Thus, the stretched PTFE tubing is regarded as one of the best vascular prostheses.
However, the porous PTFE tubing of PTFE produced by stretching is not completely free from formation of thrombus and still has room for improvement. The stretched PTFE tu~ing also has the disadvantage that when it is used as a vascular prosthesis and ~oined with ~he living body, the needle or suture tends to 7C~5 1 tear the tubing. Moreover, it is difficult for natural occlusion of suture holes to occur ~ase~ on the elasticity of the porous PTFE tubing alone, and bleeding from the suture holes is sometimes noted after the junction operation. Another problem is the low ability of the outside surface of the porous PTFE tubing to connect with the surrounding tissues of a patient.
The present invention offers a solution to these problems.
SUMMAR~ OF THE INVENTION
It is an object of this invention to provide a vascular prosthesis which is free ~rom the formation of thrombus and tearing and permits natural occlusion of suture holes.
According to this invention, there is provided a vascular prosthesis comprising a porous tubing of polytetrafluoroethylene containing an anti-coagulant su~stance and bonded to its outside surface, a porous elastomer coating containing a su~stance which counteracts the anti-coagulant.
DETAILED DESCRIPTION OF THE IN~ENTION
Since the vascular prosthesis of this invention contains an anti-coagulant substance, thrombi do not form on its inside surface. The provision of the porous elastomer coating obviates the problem of tube tearing, and suture holes are occluded under the elasticity of the coating. Should bleeding occur in the sutured areas, it will be stopped by the counteracting substance contained in the coated portion. This substance can further prevent bleeding incident to the leak~age of the anti-coayulant substance.
In addition, the ability of the tubing to conne~t wlth the surround-ing tissues of a patient is increased by the porous elastomer coat-ing The porous tubing of PTFE in accordance with this invention is produced by the method described in Japanese Patent Publication s 1 No. 13560/67 and, e.g., U~S. Patents 3,962,153 and 3,953,566. A
liquid lubricant is mixed with an unsintered powder of polytetra-fluoroethylene, and the mixture is extruded into a tubular form ~y a ram-type extruder. The PTFE used in this invention preferably has a molecular weight of 106 to 107. The tubing is stretched at least monoaxially after the li~uid lu~ricant is optionally removed from it. The tubing is then heated at a temperature above about 327C which is the sintering temperature while fixing it in place to avoid shrinkage. Thus, the stretched and expanded 1~ structure is fixed to give a tubing having increased strength.
The resulting porous PTFE tubing has a microstructure composed of very fine fibers and nodes connected to one another by these fibers. Because t~e diameters and lengths o these fiber~ and the sizes and number of the nodes can be varied depending upon the stretching and sintering conditions, the pore diameter and porosity of the resulting porous tubing can be freely determined. It has been clinically confirmed that as a vascular prosthesis it suitably has an average pore diameter of about 2~m to about 100 ~m, a poroslty of at least about 70~, and a wall thickness of about 0.3 to about 1.0 mm, In a preferred form of the microstructure of the porous PTFE tubing used in this invention, the fibers are distributed not unidirectionally but radially. This fibrous structure is obtained by biaxially stretching the PTFE tubing, namely by stretching it in the axial direction and expanding its diameter.
Expansion of its diameter can be achieved by reducing the pressure on the outside surface of the tubing, or applying pressure to its inside surface, or simultaneously performing these two procedures.
Alternatively, the diameter of the tubing may ~e mechanically enlarged by passing an ar-ticle of a suitable configuration through 114()7~i 1 the inside of the tubing. Stretching of the tubing in the axial direction and expansion of its diameter are carried out simul-taneously or successively, or may be carried out simultaneously with the final sintering step. The porous PTFE tubing o~tainea by the biaxial stretching method is more pliable and less prone to longitudinal tearing than a porous PTFE tubing stretched only in the axial direction, because the fibers are distributed not only in the axial direction ~ut radially in all directions. However, for use as a vascular prosthesis, it still leaves room for improvement.
The porous elastomer coa~ing is used in this invention for the purpose of preventing tearing of the tubing, stopping ~leeding by occlusion of suture holes by the elastomer, and increasing the ability of the tubing to connect with the surrounding tissues of a patient.
Any elastomer can be used in this invention whic~ does not harm the body. Examples are fluorine ru~ber, silicone rubber, urethane rubber, acrylic rubber, and natural rubber. Usually, elastomers are used in the crosslinked state, and in this invention, ~ too, the elastomers are used preferably in the crosslinked-state in order to prevent their deterioration in the living body.
For use as a vascular prosthesis, the suitable average pore diameter of the porous elastomer coating is from about lO~m to a~out 500 ~m, a sufficient thickness of the coating is equal to, or smaller than, the wall thickness of t~e porous PTFE tubing, i.e., a~out 20~1m to about 500~m, and the elastomer has a porosity of about 50% to about ~0%.
A porous coating of the elastomer can ~e formed on the outside surface of the porous PTFE tubing by a variety of methods including a method comprising wrapping a separately prepared porous sheet of the elastomer about the outside surface of the tubing and 7C~S
1 bonding it, a method comprising coating a solution of an elastomer comp3und containing a ~lowing agent on the outside surface of the tubing and then decomposing the blowing agent, a method comprising coating a solution of an elastomer compound having a soluble substance dispersed therein on the outside surface of the tubing, and dissolving the soluble substance to form a porous structure, a method comprising dissolving an elastomer compound in a mixture of a solvent and a nonsolvent, coating the solution on the outside surface of the tubing, and dr~ing the coating to render it porous, or a method comprising coating a solution of an elastomer compound on the outside surface of the tubing, and removing the residual solvent ~y dippiny the coated tubing in a nonsolvent bath or heat-ing it to a temperature a~ove the boiling point of the solvent, thereby to render the coating porous.
In the particular, a method for forming a porous coating of an elastomer, which comprises coating the outside surface of porous tubing of PTFE with a solution of an elastomer compound or a liquid elastomer compound, and before drying the elastomer coat-ing, applying a negative pressure to the inside wall o the porous tubing with a gas or liquid whereupon passing through the elastomer the gas or liquid forms the elastomer and thus renders the coatingporous has been found to be most suitable for the o~ject of this invention. The term "negative pressure'r as used herein denotes a pressure greater on the inside wall than the outside wall of the tubing. A pressure of about 0.05 to 1 kg/cm2 is usually applied to the inside wall of the tubing. A preferred viscosity of the elastomeric coating before forming is from about 100 to about 5,000 c.p~ at 25C.
The elastomer compound, as used herein, denotes a mixture of the elastomer with a crosslinking agent, etc.
07~
1 In the resulting structure comprising the porous PTFE
tubing and the porous elastomer coating ~onded to its outside surface, the porous PTF~ tubing portion contains an ant-coagulant substance, and the porous elastomer coating contains a substance which counteracts the anti-coagulant substance.
The anti-coagulant substance serves to increase the anti-coagulating property of the inside surface of the porous PTFE tubing, and to provide an artificial vessel which shows a high patency rate without the formation of thrombus. It is provided ~ithin the pores of the porous PTFE tubing. The anti-coagulant su~stance may be provided uniformly over all the por~s of th~
porous PTFE tubing, but is preferably only on the inside surface of the tubing.
Examples of the anti-coagulant substance include polysaccharide sulfates such as heparin, its derivatives, chondroitin sulfate, charonin sulfate, and organic acids such as citric acid. Heparin sodium is most effective and is most easily availabe.
To provide the anti-coagulant substance in the pores of 29 the porous PTFE tubing, the tubing is dipped in a solution of the anti-coagulant substance and dried. Or a polymeric gel or the like is provided within the pores, and the anti-coagulating substance i5 held therein. The latter method generally gives better results with regard to the durability of the anti-coagulating property of the substance. Examples of materials for the polymeric gel include synthetic water-soluble polymers such as polyvinyl alcohol, polyethylene oxide, polyethylene glycol, polyvinyl pyrrolidone and poly acrylic acid, and natural hydrophilic polymers such as cellulose derivatives, pectin, and alginic acid.
The anti-coagulant substance may be held in the PTFE
~140q~
1 tubing by mixing it with a solution of the above polymer, impreg-nating the pores of th~ porous PTFE tubing with. the solution, and gelling the solution by a method suitable for the respective polymer (the term "gelling" includes cross-linking). Another effective method comprising impregnating the pores o-f the PTFE
tubing with a solution of a polymeric amine such as polyethyleneimine or polyvinyl-amine, crosslinking the polymer, quaternizing it, and contacting the product with a solution of heparin sodium or the like to bond heparin ionically as described in Japanese Patent tO Application (OPI) No. 13694/1979 published E`ebruary 1, 19~'~ (The term "OPI" as used herein refers to a "published unexamined Japanese patent application") corresponding to U.S. Patent Application Serial No. 921,680, filed July 3, 1978. It has already been found that ionically bonded heparin or the like has a better anti-coagulating effect than that bonded by other methods, and its effect lasts for an extended period of time. In the present invention, too, this bonding method has been found to be most effective.
When a hydrophilic polymer is used to hold the anit-coagulant substance, it results in the formation of a hydrophilic portion on the surface of PTFE which is highly waterrepellen-t, and therefore, the product also shows an anti-coagulant effect attributed to a balanced combination of water repellency and hydrophilicity. Coupled with the activity of the anti-coagulant substance, this provides a vascular prosthesis having superior properties. A suitable concentration for the polymeric solution is usually not more than 10 wt%, and the suitable concentration for the anti-coagulant substance is in the range oE about 0.2 to 5 wt~ (in the case of heparin sodium). Conveniently, impregnation is performed only on the inside surface of the porous PTFE -tubing such that the anti-coagulating property of onl.y the inside surface is increased.
1~40~7~5 1 The counteracting subs~ance for the anti-coagulant su~stance in this invention is contained in the porous elastomer coating portion, and serves to stop bleeding. The counteracting substance includes a substance which acts in a way opposite to the anti-coagulant substance on the inside surface of the tu~ing, and a su~stance which reduces or nullifies the function of the anti-coagulant. Example~ of the counteracting su~stance are inorganic or organic coagulating substances such as silica, alumina, car~on black, or activated carbon, and antagonistic agents against anti-coagulant substances. Typical examples oE antagonistic agents against heparin are protamine~ and its derivatives such as protamine sulfate and protamine zinc.
Such a counteracting substance may be incorporated into the elastomer as a filler, or provided in the pores of the porous elastomèr coating. When it is mixed with the elastomer, its amount is sufficiently up to 10% by weight based on the weight of the elastomer. When it is provided in the pores of the elastomer coating, its amount may be small. Desirably, it is used in an amount larger than that which is required to nullify the entire ~ amount of the anit-coagulant substance.
The provision of the coagulating substance in the pores of the elastomer coating is suitably achieved by impregnating the porous elastomer with a dispersion of coagu~ating substance and drying the impregnated elastomer. It has been confirmed that the coagulating substancQ present in-the pores of the elastomer will not come out. In order to fix the coagulating substance onto the inner surface of the pores a binder may be used or the part of the elastomer may be dissol~ed and resolidified to bind the coagulating su~stance.
As described in detail hereinabove, the vascular ~40~Q5 1 prosthesis of this invention is an improvement over a conventional vascular prosthesis composed mainly of a porous PTFE tubing, and also is given a high level of function, exhibiting characteristics not seen in the prior art.
While the invention has been described in detail and with reference to specific em~odiments thereof, it will be apparent ~o one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof~
_g_
Claims (16)
1. A vascular prosthesis comprising a porous tubing of polytetrafluoroethylene containing an anti-coagulant substance and bonded to its outside surface a porous elastomer coating containing a substance which counteracts the anti-coagulant substance.
2. The vascular prosthesis of Claim 1, wherein said anti-coagulant substance is heparin or its derivative.
3. The vascular prosthesis of Claim 1, wherein said counteracting substance is an inorganic or organic coagulating substance.
4. The vascular prosthesis of Claim 1, wherein said counteracting substance is a heparin antagonist.
5. The vascular prosthesis of Claim 4, wherein said heparin antagonist is protamine or its derivative.
6. The vascular prosthesis of Claim 1, wherein said PTFE
tubing has a pore diameter of about 2 to about 100 µm, a porosity of at least about 70% and a wall thickness of about 0.3 to 1.0 mm.
tubing has a pore diameter of about 2 to about 100 µm, a porosity of at least about 70% and a wall thickness of about 0.3 to 1.0 mm.
7. The vascular prosthesis of Claim 1, wherein said elastomer is selected from the group consisting of fluorine rubber, silicone rubber, urethane rubber, acrylic rubber, and natural rubber.
8. The vascular prosthesis of Claim 7, wherein said elastomer has a porosity of about 50% to about 90%.
9. The vascular prosthesis of Claim 7, wherein said elastomer coating is about 20 to about 500 µm thick.
10. The vascular prosthesis of Claim 1, wherein said anti-coagulant is selected from the group consisting of polysaccharide sulfates and organic acids.
11. The vascular prosthesis of Claim 1, wherein said anti-coagulant is contained in said PTFE tubing dispersed in a polymeric gel.
12. The vascular prosthesis of Claim 2, wherein said heparin or derivatives thereof is contained in said PTFE tubing ionically bonded to a crosslinked polymeric amine.
13. The vascular prosthesis of Claim 12, wherein said anti-coagulant is contained in said polymeric gel in an amount of about 0.2 to 5% by weight.
14. The vascular prosthesis of Claim 1, wherein said substance is selected from the group consisting of silica, alumina, carbon black, activated carbon, and antagonistic agents for anti-coagulants.
15. The vascular prosthesis of Claim 1, wherein said substance is present with said elastomer in an amount of about 0.5% to about 10% by weight based on the weight of the elastomer.
16. The vascular prosthesis of claim 10, wherein said anti-coagulant is selected from the group consisting of heparin and derivatives thereof, chondroitin sulfate, charonin sulfate, and citric acid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP128695/78 | 1978-10-18 | ||
JP53128695A JPS6037735B2 (en) | 1978-10-18 | 1978-10-18 | Artificial blood vessel |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1140705A true CA1140705A (en) | 1983-02-08 |
Family
ID=14991125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000337441A Expired CA1140705A (en) | 1978-10-18 | 1979-10-12 | Vascular prosthesis |
Country Status (11)
Country | Link |
---|---|
US (1) | US4321711A (en) |
JP (1) | JPS6037735B2 (en) |
AU (1) | AU528494B2 (en) |
BE (1) | BE879356A (en) |
CA (1) | CA1140705A (en) |
DE (1) | DE2941281A1 (en) |
FR (1) | FR2439005A1 (en) |
GB (1) | GB2033232B (en) |
IT (1) | IT1128744B (en) |
NL (1) | NL7907532A (en) |
SE (1) | SE443288B (en) |
Families Citing this family (240)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE444640B (en) * | 1980-08-28 | 1986-04-28 | Bergentz Sven Erik | IN ANIMAL OR HUMAN IMPLANTABLE KERLPROTES AND SET FOR ITS MANUFACTURING |
US4604762A (en) * | 1981-02-13 | 1986-08-12 | Thoratec Laboratories Corporation | Arterial graft prosthesis |
JPS58136122U (en) * | 1982-03-06 | 1983-09-13 | 株式会社潤工社 | Artificial blood vessel |
JPS58180162A (en) * | 1982-04-19 | 1983-10-21 | 株式会社高研 | Anti-thrombosis medical material |
DE3370138D1 (en) * | 1982-05-14 | 1987-04-16 | Astra Meditec Ab | Articles exhibiting a biocompatible surface layer and process for providing articles with such a surface layer |
US4546499A (en) * | 1982-12-13 | 1985-10-15 | Possis Medical, Inc. | Method of supplying blood to blood receiving vessels |
EP0128501B1 (en) * | 1983-06-06 | 1989-03-29 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel and process for preparing the same |
EP0130401B1 (en) * | 1983-06-06 | 1989-05-17 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel and process for preparing the same |
DE3329733A1 (en) * | 1983-08-17 | 1985-03-07 | Johannes Dr.med. 6500 Mainz Reinmüller | PLASTIC IMPLANT |
US4521564A (en) * | 1984-02-10 | 1985-06-04 | Warner-Lambert Company | Covalent bonded antithrombogenic polyurethane material |
DE3566498D1 (en) * | 1984-03-01 | 1989-01-05 | Kanegafuchi Chemical Ind | Artificial vessel and process for preparing the same |
US4687482A (en) * | 1984-04-27 | 1987-08-18 | Scripps Clinic And Research Foundation | Vascular prosthesis |
GB8418018D0 (en) * | 1984-07-16 | 1984-08-22 | Johnson & Johnson | Connective tissue prosthesis |
EP0217115B1 (en) * | 1985-08-26 | 1989-10-25 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Artificial vessel |
US4699141A (en) * | 1986-01-16 | 1987-10-13 | Rhode Island Hospital | Neovascularization |
EP0241838B1 (en) * | 1986-04-07 | 1992-04-15 | Agency Of Industrial Science And Technology | Antithrombogenic material |
DE3627487A1 (en) * | 1986-08-13 | 1988-02-25 | Bernd Dr Steckmeier | Vascular prosthesis |
NZ222089A (en) * | 1986-10-20 | 1993-03-26 | Malcolm B Herring | Endothelial cell harvester with irrigation means for enzyme treatment of blood vessel |
EP0269449A3 (en) * | 1986-11-26 | 1988-12-21 | BAXTER INTERNATIONAL INC. (a Delaware corporation) | Porous flexible radially expanded fluoropolymers and process for producing the same |
JPS63209647A (en) * | 1987-02-26 | 1988-08-31 | 鐘淵化学工業株式会社 | Artificial blood vessel |
US5061276A (en) * | 1987-04-28 | 1991-10-29 | Baxter International Inc. | Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation |
US4849285A (en) * | 1987-06-01 | 1989-07-18 | Bio Med Sciences, Inc. | Composite macrostructure of ceramic and organic biomaterials |
US5219361A (en) * | 1988-09-16 | 1993-06-15 | Clemson University | Soft tissue implant with micron-scale surface texture to optimize anchorage |
US5011494A (en) * | 1988-09-16 | 1991-04-30 | Clemson University | Soft tissue implant with micron-scale surface texture to optimize anchorage |
CA1322628C (en) * | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
US4957669A (en) * | 1989-04-06 | 1990-09-18 | Shiley, Inc. | Method for producing tubing useful as a tapered vascular graft prosthesis |
WO1990013332A1 (en) * | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
US5100422A (en) * | 1989-05-26 | 1992-03-31 | Impra, Inc. | Blood vessel patch |
US5104400A (en) * | 1989-05-26 | 1992-04-14 | Impra, Inc. | Blood vessel patch |
US5152782A (en) * | 1989-05-26 | 1992-10-06 | Impra, Inc. | Non-porous coated ptfe graft |
US4955899A (en) * | 1989-05-26 | 1990-09-11 | Impra, Inc. | Longitudinally compliant vascular graft |
US5197882A (en) * | 1990-05-14 | 1993-03-30 | Gary R. Jernberg | Periodontal barrier and method for aiding periodontal tissue regeneration agents |
US5059123A (en) * | 1990-05-14 | 1991-10-22 | Jernberg Gary R | Periodontal barrier and method for aiding periodontal tissue regeneration |
US5290271A (en) * | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
EP0528971B1 (en) * | 1990-05-14 | 1999-09-01 | JERNBERG, Gary R. | Surgical implant and method incorporating chemotherapeutic agents |
CA2070816A1 (en) * | 1990-10-31 | 1992-05-01 | James H. Brauker | Close vascularization implant material |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US6197325B1 (en) | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US7196054B1 (en) | 1990-11-27 | 2007-03-27 | The American National Red Cross | Methods for treating wound tissue and forming a supplemented fibrin matrix |
US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
EP0587588B1 (en) * | 1991-06-04 | 1998-07-08 | Donaldson Company, Inc. | Fluid treated polytetrafluoroethylene products and their manufacture |
US6033437A (en) | 1991-09-30 | 2000-03-07 | Orbital Implant Technology | Pegs for orbital implants |
DE69325649T2 (en) * | 1992-03-13 | 1999-11-18 | Atrium Medical Corp | OBJECTS OF EXPANDED FLUOROPOLYMER (e.g. POLYTETRAFLUORETHYLENE) WITH CONTROLLED POROSITY AND ITS PRODUCTION |
US5246452A (en) * | 1992-04-13 | 1993-09-21 | Impra, Inc. | Vascular graft with removable sheath |
US5354329A (en) * | 1992-04-17 | 1994-10-11 | Whalen Biomedical, Inc. | Vascular prosthesis having enhanced compatibility and compliance characteristics |
US5383927A (en) * | 1992-05-07 | 1995-01-24 | Intervascular Inc. | Non-thromogenic vascular prosthesis |
DE4222380A1 (en) * | 1992-07-08 | 1994-01-13 | Ernst Peter Prof Dr M Strecker | Endoprosthesis implantable percutaneously in a patient's body |
US5443458A (en) * | 1992-12-22 | 1995-08-22 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method of manufacture |
WO1994021196A2 (en) * | 1993-03-18 | 1994-09-29 | C.R. Bard, Inc. | Endovascular stents |
US20020055710A1 (en) * | 1998-04-30 | 2002-05-09 | Ronald J. Tuch | Medical device for delivering a therapeutic agent and method of preparation |
JPH0767895A (en) * | 1993-06-25 | 1995-03-14 | Sumitomo Electric Ind Ltd | Antimicrobial artificial blood vessel and suture yarn for antimicrobial operation |
US5653760A (en) * | 1993-08-30 | 1997-08-05 | Saffran; Bruce N. | Method and apparatus for managing macromolecular distribution |
US5466262A (en) * | 1993-08-30 | 1995-11-14 | Saffran; Bruce N. | Malleable fracture stabilization device with micropores for directed drug delivery |
JPH07250887A (en) * | 1994-03-15 | 1995-10-03 | Seikagaku Kogyo Co Ltd | Artificial blood vessel and its production |
US5584876A (en) * | 1994-04-29 | 1996-12-17 | W. L. Gore & Associates, Inc. | Cell excluding sheath for vascular grafts |
WO1996000103A1 (en) * | 1994-06-27 | 1996-01-04 | Endomed, Inc. | Radially expandable polytetrafluoroethylene and expandable endovascular stents formed therewith |
US6156305A (en) * | 1994-07-08 | 2000-12-05 | Baxter International Inc. | Implanted tumor cells for the prevention and treatment of cancer |
US5578073A (en) * | 1994-09-16 | 1996-11-26 | Ramot Of Tel Aviv University | Thromboresistant surface treatment for biomaterials |
IL115321A (en) * | 1994-09-16 | 2000-08-31 | Univ Ramot | Thromboresistant surface treatment for biomaterials |
DE69521709T2 (en) * | 1994-09-23 | 2002-04-25 | Impra Inc | CARBON-BASED VESSEL TRANSPLANT AND MANUFACTURING METHOD |
US5782789A (en) * | 1994-10-19 | 1998-07-21 | Atrium Medical Corporation | Macrochannel phosthetic/delivery patch |
JP2911763B2 (en) * | 1994-10-27 | 1999-06-23 | 三桜子 布川 | Artificial blood vessel |
US5820917A (en) * | 1995-06-07 | 1998-10-13 | Medtronic, Inc. | Blood-contacting medical device and method |
US20050152950A1 (en) * | 1995-11-13 | 2005-07-14 | Saffran Bruce N. | Method and apparatus for macromolecular delivery using a coated membrane |
CA2197375C (en) * | 1996-02-15 | 2003-05-06 | Yasuhiro Okuda | Artificial blood vessel |
US5810836A (en) * | 1996-03-04 | 1998-09-22 | Myocardial Stents, Inc. | Device and method for trans myocardial revascularization (TMR) |
US5769884A (en) * | 1996-06-27 | 1998-06-23 | Cordis Corporation | Controlled porosity endovascular implant |
US5851229A (en) * | 1996-09-13 | 1998-12-22 | Meadox Medicals, Inc. | Bioresorbable sealants for porous vascular grafts |
US6010529A (en) * | 1996-12-03 | 2000-01-04 | Atrium Medical Corporation | Expandable shielded vessel support |
US5925074A (en) * | 1996-12-03 | 1999-07-20 | Atrium Medical Corporation | Vascular endoprosthesis and method |
US6240616B1 (en) * | 1997-04-15 | 2001-06-05 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing a medicated porous metal prosthesis |
US10028851B2 (en) * | 1997-04-15 | 2018-07-24 | Advanced Cardiovascular Systems, Inc. | Coatings for controlling erosion of a substrate of an implantable medical device |
US8172897B2 (en) * | 1997-04-15 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Polymer and metal composite implantable medical devices |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6776792B1 (en) | 1997-04-24 | 2004-08-17 | Advanced Cardiovascular Systems Inc. | Coated endovascular stent |
US5861035A (en) * | 1997-05-23 | 1999-01-19 | Griffith; Donald P. | Modular prosthetic conduit |
US6203536B1 (en) * | 1997-06-17 | 2001-03-20 | Medtronic, Inc. | Medical device for delivering a therapeutic substance and method therefor |
US6106454A (en) * | 1997-06-17 | 2000-08-22 | Medtronic, Inc. | Medical device for delivering localized radiation |
US6123957A (en) * | 1997-07-16 | 2000-09-26 | Jernberg; Gary R. | Delivery of agents and method for regeneration of periodontal tissues |
US5854382A (en) * | 1997-08-18 | 1998-12-29 | Meadox Medicals, Inc. | Bioresorbable compositions for implantable prostheses |
US6316522B1 (en) | 1997-08-18 | 2001-11-13 | Scimed Life Systems, Inc. | Bioresorbable hydrogel compositions for implantable prostheses |
US6762336B1 (en) | 1998-01-19 | 2004-07-13 | The American National Red Cross | Hemostatic sandwich bandage |
US6063117A (en) * | 1998-01-22 | 2000-05-16 | Perry; Arthur C. | Porous orbital implant structure |
US7208011B2 (en) * | 2001-08-20 | 2007-04-24 | Conor Medsystems, Inc. | Implantable medical device with drug filled holes |
US7208010B2 (en) * | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
US6013099A (en) | 1998-04-29 | 2000-01-11 | Medtronic, Inc. | Medical device for delivering a water-insoluble therapeutic salt or substance |
US7807211B2 (en) * | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US6527801B1 (en) * | 2000-04-13 | 2003-03-04 | Advanced Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US8109994B2 (en) * | 2003-01-10 | 2012-02-07 | Abbott Cardiovascular Systems, Inc. | Biodegradable drug delivery material for stent |
US7875283B2 (en) * | 2000-04-13 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Biodegradable polymers for use with implantable medical devices |
US20050002986A1 (en) * | 2000-05-12 | 2005-01-06 | Robert Falotico | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US7300662B2 (en) | 2000-05-12 | 2007-11-27 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US8236048B2 (en) | 2000-05-12 | 2012-08-07 | Cordis Corporation | Drug/drug delivery systems for the prevention and treatment of vascular disease |
US6805898B1 (en) * | 2000-09-28 | 2004-10-19 | Advanced Cardiovascular Systems, Inc. | Surface features of an implantable medical device |
CA2424029C (en) | 2000-09-29 | 2008-01-29 | Cordis Corporation | Coated medical devices |
US6783793B1 (en) | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
US6770086B1 (en) * | 2000-11-02 | 2004-08-03 | Scimed Life Systems, Inc. | Stent covering formed of porous polytetraflouroethylene |
US6648911B1 (en) | 2000-11-20 | 2003-11-18 | Avantec Vascular Corporation | Method and device for the treatment of vulnerable tissue site |
US6565659B1 (en) | 2001-06-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Stent mounting assembly and a method of using the same to coat a stent |
US7056338B2 (en) * | 2003-03-28 | 2006-06-06 | Conor Medsystems, Inc. | Therapeutic agent delivery device with controlled therapeutic agent release rates |
US7285304B1 (en) | 2003-06-25 | 2007-10-23 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
US7989018B2 (en) * | 2001-09-17 | 2011-08-02 | Advanced Cardiovascular Systems, Inc. | Fluid treatment of a polymeric coating on an implantable medical device |
US6863683B2 (en) | 2001-09-19 | 2005-03-08 | Abbott Laboratoris Vascular Entities Limited | Cold-molding process for loading a stent onto a stent delivery system |
JP2003126125A (en) * | 2001-10-24 | 2003-05-07 | Katsuko Sakai | Artificial blood vessel and method of preparing it |
US7789908B2 (en) * | 2002-06-25 | 2010-09-07 | Boston Scientific Scimed, Inc. | Elastomerically impregnated ePTFE to enhance stretch and recovery properties for vascular grafts and coverings |
CN1327905C (en) | 2002-09-10 | 2007-07-25 | 美国国家红十字会 | Hemostatic dressing |
US20060271168A1 (en) * | 2002-10-30 | 2006-11-30 | Klaus Kleine | Degradable medical device |
CA2505576A1 (en) * | 2002-11-08 | 2004-05-27 | Conor Medsystems, Inc. | Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor |
US7758881B2 (en) * | 2004-06-30 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US8435550B2 (en) * | 2002-12-16 | 2013-05-07 | Abbot Cardiovascular Systems Inc. | Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device |
US20040202692A1 (en) * | 2003-03-28 | 2004-10-14 | Conor Medsystems, Inc. | Implantable medical device and method for in situ selective modulation of agent delivery |
EP1610823B1 (en) * | 2003-03-28 | 2011-09-28 | Innovational Holdings, LLC | Implantable medical device with continuous agent concentration gradient |
US7186789B2 (en) * | 2003-06-11 | 2007-03-06 | Advanced Cardiovascular Systems, Inc. | Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings |
US20050118344A1 (en) * | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
US7198675B2 (en) | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
US20050100577A1 (en) * | 2003-11-10 | 2005-05-12 | Parker Theodore L. | Expandable medical device with beneficial agent matrix formed by a multi solvent system |
US7563324B1 (en) | 2003-12-29 | 2009-07-21 | Advanced Cardiovascular Systems Inc. | System and method for coating an implantable medical device |
EP1713634B1 (en) | 2003-12-30 | 2013-07-24 | Boston Scientific Limited | Method of uniaxially expanding a fluoropolymer tube |
US20050214339A1 (en) * | 2004-03-29 | 2005-09-29 | Yiwen Tang | Biologically degradable compositions for medical applications |
US7553377B1 (en) | 2004-04-27 | 2009-06-30 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for electrostatic coating of an abluminal stent surface |
US20060206200A1 (en) * | 2004-05-25 | 2006-09-14 | Chestnut Medical Technologies, Inc. | Flexible vascular occluding device |
US8617234B2 (en) * | 2004-05-25 | 2013-12-31 | Covidien Lp | Flexible vascular occluding device |
US8623067B2 (en) | 2004-05-25 | 2014-01-07 | Covidien Lp | Methods and apparatus for luminal stenting |
US8267985B2 (en) * | 2005-05-25 | 2012-09-18 | Tyco Healthcare Group Lp | System and method for delivering and deploying an occluding device within a vessel |
EP1750619B1 (en) | 2004-05-25 | 2013-07-24 | Covidien LP | Flexible vascular occluding device |
SG175723A1 (en) | 2004-05-25 | 2011-12-29 | Tyco Healthcare | Vascular stenting for aneurysms |
US8568469B1 (en) | 2004-06-28 | 2013-10-29 | Advanced Cardiovascular Systems, Inc. | Stent locking element and a method of securing a stent on a delivery system |
US8241554B1 (en) | 2004-06-29 | 2012-08-14 | Advanced Cardiovascular Systems, Inc. | Method of forming a stent pattern on a tube |
US8747879B2 (en) * | 2006-04-28 | 2014-06-10 | Advanced Cardiovascular Systems, Inc. | Method of fabricating an implantable medical device to reduce chance of late inflammatory response |
US8778256B1 (en) | 2004-09-30 | 2014-07-15 | Advanced Cardiovascular Systems, Inc. | Deformation of a polymer tube in the fabrication of a medical article |
US7731890B2 (en) * | 2006-06-15 | 2010-06-08 | Advanced Cardiovascular Systems, Inc. | Methods of fabricating stents with enhanced fracture toughness |
US8747878B2 (en) | 2006-04-28 | 2014-06-10 | Advanced Cardiovascular Systems, Inc. | Method of fabricating an implantable medical device by controlling crystalline structure |
US7971333B2 (en) * | 2006-05-30 | 2011-07-05 | Advanced Cardiovascular Systems, Inc. | Manufacturing process for polymetric stents |
US20060041102A1 (en) * | 2004-08-23 | 2006-02-23 | Advanced Cardiovascular Systems, Inc. | Implantable devices comprising biologically absorbable polymers having constant rate of degradation and methods for fabricating the same |
US9283099B2 (en) * | 2004-08-25 | 2016-03-15 | Advanced Cardiovascular Systems, Inc. | Stent-catheter assembly with a releasable connection for stent retention |
US7229471B2 (en) * | 2004-09-10 | 2007-06-12 | Advanced Cardiovascular Systems, Inc. | Compositions containing fast-leaching plasticizers for improved performance of medical devices |
US8043553B1 (en) | 2004-09-30 | 2011-10-25 | Advanced Cardiovascular Systems, Inc. | Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article |
US7875233B2 (en) | 2004-09-30 | 2011-01-25 | Advanced Cardiovascular Systems, Inc. | Method of fabricating a biaxially oriented implantable medical device |
US8173062B1 (en) | 2004-09-30 | 2012-05-08 | Advanced Cardiovascular Systems, Inc. | Controlled deformation of a polymer tube in fabricating a medical article |
US8029563B2 (en) | 2004-11-29 | 2011-10-04 | Gore Enterprise Holdings, Inc. | Implantable devices with reduced needle puncture site leakage |
US7632307B2 (en) | 2004-12-16 | 2009-12-15 | Advanced Cardiovascular Systems, Inc. | Abluminal, multilayer coating constructs for drug-delivery stents |
US20060224226A1 (en) * | 2005-03-31 | 2006-10-05 | Bin Huang | In-vivo radial orientation of a polymeric implantable medical device |
US7381048B2 (en) * | 2005-04-12 | 2008-06-03 | Advanced Cardiovascular Systems, Inc. | Stents with profiles for gripping a balloon catheter and molds for fabricating stents |
US7291166B2 (en) * | 2005-05-18 | 2007-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric stent patterns |
CA2843097C (en) | 2005-05-24 | 2015-10-27 | Inspire M.D Ltd. | Stent apparatuses for treatment via body lumens and methods of use |
US8043323B2 (en) | 2006-10-18 | 2011-10-25 | Inspiremd Ltd. | In vivo filter assembly |
US8961586B2 (en) * | 2005-05-24 | 2015-02-24 | Inspiremd Ltd. | Bifurcated stent assemblies |
JP4945714B2 (en) | 2005-05-25 | 2012-06-06 | タイコ ヘルスケア グループ リミテッド パートナーシップ | System and method for supplying and deploying an occlusion device in a conduit |
US8273101B2 (en) | 2005-05-25 | 2012-09-25 | Tyco Healthcare Group Lp | System and method for delivering and deploying an occluding device within a vessel |
US7622070B2 (en) * | 2005-06-20 | 2009-11-24 | Advanced Cardiovascular Systems, Inc. | Method of manufacturing an implantable polymeric medical device |
US20060292690A1 (en) * | 2005-06-22 | 2006-12-28 | Cesco Bioengineering Co., Ltd. | Method of making cell growth surface |
US7658880B2 (en) * | 2005-07-29 | 2010-02-09 | Advanced Cardiovascular Systems, Inc. | Polymeric stent polishing method and apparatus |
US7297758B2 (en) * | 2005-08-02 | 2007-11-20 | Advanced Cardiovascular Systems, Inc. | Method for extending shelf-life of constructs of semi-crystallizable polymers |
US20070038290A1 (en) * | 2005-08-15 | 2007-02-15 | Bin Huang | Fiber reinforced composite stents |
US7476245B2 (en) * | 2005-08-16 | 2009-01-13 | Advanced Cardiovascular Systems, Inc. | Polymeric stent patterns |
US20070045252A1 (en) * | 2005-08-23 | 2007-03-01 | Klaus Kleine | Laser induced plasma machining with a process gas |
US20070045255A1 (en) * | 2005-08-23 | 2007-03-01 | Klaus Kleine | Laser induced plasma machining with an optimized process gas |
US9248034B2 (en) * | 2005-08-23 | 2016-02-02 | Advanced Cardiovascular Systems, Inc. | Controlled disintegrating implantable medical devices |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
US20070148251A1 (en) * | 2005-12-22 | 2007-06-28 | Hossainy Syed F A | Nanoparticle releasing medical devices |
US20070151961A1 (en) * | 2006-01-03 | 2007-07-05 | Klaus Kleine | Fabrication of an implantable medical device with a modified laser beam |
US20070156230A1 (en) | 2006-01-04 | 2007-07-05 | Dugan Stephen R | Stents with radiopaque markers |
US7951185B1 (en) | 2006-01-06 | 2011-05-31 | Advanced Cardiovascular Systems, Inc. | Delivery of a stent at an elevated temperature |
US20070179219A1 (en) * | 2006-01-31 | 2007-08-02 | Bin Huang | Method of fabricating an implantable medical device using gel extrusion and charge induced orientation |
US8152833B2 (en) | 2006-02-22 | 2012-04-10 | Tyco Healthcare Group Lp | Embolic protection systems having radiopaque filter mesh |
US7964210B2 (en) * | 2006-03-31 | 2011-06-21 | Abbott Cardiovascular Systems Inc. | Degradable polymeric implantable medical devices with a continuous phase and discrete phase |
US20070254012A1 (en) * | 2006-04-28 | 2007-11-01 | Ludwig Florian N | Controlled degradation and drug release in stents |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US7761968B2 (en) * | 2006-05-25 | 2010-07-27 | Advanced Cardiovascular Systems, Inc. | Method of crimping a polymeric stent |
US7951194B2 (en) | 2006-05-26 | 2011-05-31 | Abbott Cardiovascular Sysetms Inc. | Bioabsorbable stent with radiopaque coating |
US8752268B2 (en) | 2006-05-26 | 2014-06-17 | Abbott Cardiovascular Systems Inc. | Method of making stents with radiopaque markers |
US7959940B2 (en) * | 2006-05-30 | 2011-06-14 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical devices |
US8343530B2 (en) * | 2006-05-30 | 2013-01-01 | Abbott Cardiovascular Systems Inc. | Polymer-and polymer blend-bioceramic composite implantable medical devices |
US20070282434A1 (en) * | 2006-05-30 | 2007-12-06 | Yunbing Wang | Copolymer-bioceramic composite implantable medical devices |
US7842737B2 (en) | 2006-09-29 | 2010-11-30 | Abbott Cardiovascular Systems Inc. | Polymer blend-bioceramic composite implantable medical devices |
US20080058916A1 (en) * | 2006-05-31 | 2008-03-06 | Bin Huang | Method of fabricating polymeric self-expandable stent |
US8486135B2 (en) | 2006-06-01 | 2013-07-16 | Abbott Cardiovascular Systems Inc. | Implantable medical devices fabricated from branched polymers |
US20070281073A1 (en) * | 2006-06-01 | 2007-12-06 | Gale David C | Enhanced adhesion of drug delivery coatings on stents |
US8034287B2 (en) * | 2006-06-01 | 2011-10-11 | Abbott Cardiovascular Systems Inc. | Radiation sterilization of medical devices |
US20070282433A1 (en) * | 2006-06-01 | 2007-12-06 | Limon Timothy A | Stent with retention protrusions formed during crimping |
US20080124372A1 (en) * | 2006-06-06 | 2008-05-29 | Hossainy Syed F A | Morphology profiles for control of agent release rates from polymer matrices |
US20070286941A1 (en) * | 2006-06-13 | 2007-12-13 | Bin Huang | Surface treatment of a polymeric stent |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8535372B1 (en) | 2006-06-16 | 2013-09-17 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with prohealing layer |
US8333000B2 (en) | 2006-06-19 | 2012-12-18 | Advanced Cardiovascular Systems, Inc. | Methods for improving stent retention on a balloon catheter |
US20070290412A1 (en) * | 2006-06-19 | 2007-12-20 | John Capek | Fabricating a stent with selected properties in the radial and axial directions |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US9072820B2 (en) * | 2006-06-26 | 2015-07-07 | Advanced Cardiovascular Systems, Inc. | Polymer composite stent with polymer particles |
US8128688B2 (en) * | 2006-06-27 | 2012-03-06 | Abbott Cardiovascular Systems Inc. | Carbon coating on an implantable device |
US20070299511A1 (en) * | 2006-06-27 | 2007-12-27 | Gale David C | Thin stent coating |
US7794776B1 (en) | 2006-06-29 | 2010-09-14 | Abbott Cardiovascular Systems Inc. | Modification of polymer stents with radiation |
US7740791B2 (en) * | 2006-06-30 | 2010-06-22 | Advanced Cardiovascular Systems, Inc. | Method of fabricating a stent with features by blow molding |
US20080009938A1 (en) * | 2006-07-07 | 2008-01-10 | Bin Huang | Stent with a radiopaque marker and method for making the same |
US7823263B2 (en) | 2006-07-11 | 2010-11-02 | Abbott Cardiovascular Systems Inc. | Method of removing stent islands from a stent |
US7757543B2 (en) | 2006-07-13 | 2010-07-20 | Advanced Cardiovascular Systems, Inc. | Radio frequency identification monitoring of stents |
US7998404B2 (en) * | 2006-07-13 | 2011-08-16 | Advanced Cardiovascular Systems, Inc. | Reduced temperature sterilization of stents |
US20080014244A1 (en) * | 2006-07-13 | 2008-01-17 | Gale David C | Implantable medical devices and coatings therefor comprising physically crosslinked block copolymers |
US7794495B2 (en) * | 2006-07-17 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Controlled degradation of stents |
US7886419B2 (en) * | 2006-07-18 | 2011-02-15 | Advanced Cardiovascular Systems, Inc. | Stent crimping apparatus and method |
US8016879B2 (en) * | 2006-08-01 | 2011-09-13 | Abbott Cardiovascular Systems Inc. | Drug delivery after biodegradation of the stent scaffolding |
US20080091262A1 (en) * | 2006-10-17 | 2008-04-17 | Gale David C | Drug delivery after biodegradation of the stent scaffolding |
NZ574653A (en) * | 2006-08-04 | 2012-11-30 | Stb Lifesaving Technologies Inc | Solid dressing for treating wounded tissue |
US9173733B1 (en) | 2006-08-21 | 2015-11-03 | Abbott Cardiovascular Systems Inc. | Tracheobronchial implantable medical device and methods of use |
US7923022B2 (en) * | 2006-09-13 | 2011-04-12 | Advanced Cardiovascular Systems, Inc. | Degradable polymeric implantable medical devices with continuous phase and discrete phase |
US20100324664A1 (en) * | 2006-10-18 | 2010-12-23 | Asher Holzer | Bifurcated Stent Assemblies |
US20100204772A1 (en) * | 2006-10-18 | 2010-08-12 | Asher Holzer | Filter Assemblies |
EP2076212B1 (en) * | 2006-10-18 | 2017-03-29 | Inspiremd Ltd. | Knitted stent jackets |
CA3013758C (en) | 2006-11-22 | 2021-09-14 | Inspiremd Ltd. | Intravascular aneurysm treatment device and methods |
US8099849B2 (en) | 2006-12-13 | 2012-01-24 | Abbott Cardiovascular Systems Inc. | Optimizing fracture toughness of polymeric stent |
US20080243228A1 (en) * | 2007-03-28 | 2008-10-02 | Yunbing Wang | Implantable medical devices fabricated from block copolymers |
US8262723B2 (en) | 2007-04-09 | 2012-09-11 | Abbott Cardiovascular Systems Inc. | Implantable medical devices fabricated from polymer blends with star-block copolymers |
US7829008B2 (en) * | 2007-05-30 | 2010-11-09 | Abbott Cardiovascular Systems Inc. | Fabricating a stent from a blow molded tube |
US7959857B2 (en) * | 2007-06-01 | 2011-06-14 | Abbott Cardiovascular Systems Inc. | Radiation sterilization of medical devices |
US20080306582A1 (en) * | 2007-06-05 | 2008-12-11 | Yunbing Wang | Implantable medical devices with elastomeric copolymer coatings |
US8202528B2 (en) * | 2007-06-05 | 2012-06-19 | Abbott Cardiovascular Systems Inc. | Implantable medical devices with elastomeric block copolymer coatings |
US8293260B2 (en) * | 2007-06-05 | 2012-10-23 | Abbott Cardiovascular Systems Inc. | Elastomeric copolymer coatings containing poly (tetramethyl carbonate) for implantable medical devices |
US8425591B1 (en) | 2007-06-11 | 2013-04-23 | Abbott Cardiovascular Systems Inc. | Methods of forming polymer-bioceramic composite medical devices with bioceramic particles |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
US7901452B2 (en) * | 2007-06-27 | 2011-03-08 | Abbott Cardiovascular Systems Inc. | Method to fabricate a stent having selected morphology to reduce restenosis |
US7955381B1 (en) | 2007-06-29 | 2011-06-07 | Advanced Cardiovascular Systems, Inc. | Polymer-bioceramic composite implantable medical device with different types of bioceramic particles |
US20090075891A1 (en) * | 2007-08-06 | 2009-03-19 | Macphee Martin | Methods and dressings for sealing internal injuries |
WO2009082718A1 (en) * | 2007-12-21 | 2009-07-02 | Feinstein Ara J | Devices, systems, and methods for repair of vascular defects |
WO2009140437A1 (en) | 2008-05-13 | 2009-11-19 | Nfocus Neuromedical, Inc. | Braid implant delivery systems |
US8808353B2 (en) | 2010-01-30 | 2014-08-19 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds having a low crossing profile |
US8568471B2 (en) | 2010-01-30 | 2013-10-29 | Abbott Cardiovascular Systems Inc. | Crush recoverable polymer scaffolds |
US9045657B2 (en) | 2010-03-24 | 2015-06-02 | The Board Of Trustees Of The University Of Illinois | Viscoelastic ink for direct writing of hydrogel structures |
US8974622B2 (en) | 2010-12-28 | 2015-03-10 | Boston Scientific Scimed, Inc. | Composite ePTFE-silicone covering for stent |
US8726483B2 (en) | 2011-07-29 | 2014-05-20 | Abbott Cardiovascular Systems Inc. | Methods for uniform crimping and deployment of a polymer scaffold |
US9155647B2 (en) | 2012-07-18 | 2015-10-13 | Covidien Lp | Methods and apparatus for luminal stenting |
US9114001B2 (en) | 2012-10-30 | 2015-08-25 | Covidien Lp | Systems for attaining a predetermined porosity of a vascular device |
US9452070B2 (en) | 2012-10-31 | 2016-09-27 | Covidien Lp | Methods and systems for increasing a density of a region of a vascular device |
US9943427B2 (en) | 2012-11-06 | 2018-04-17 | Covidien Lp | Shaped occluding devices and methods of using the same |
US9157174B2 (en) | 2013-02-05 | 2015-10-13 | Covidien Lp | Vascular device for aneurysm treatment and providing blood flow into a perforator vessel |
US9814560B2 (en) | 2013-12-05 | 2017-11-14 | W. L. Gore & Associates, Inc. | Tapered implantable device and methods for making such devices |
KR20170052626A (en) | 2014-09-05 | 2017-05-12 | 심바이오믹스 세러퓨틱스 엘엘씨 | Secnidazole for use in the treatment of bacterial vaginosis |
US9999527B2 (en) | 2015-02-11 | 2018-06-19 | Abbott Cardiovascular Systems Inc. | Scaffolds having radiopaque markers |
CN110946684B (en) | 2015-06-05 | 2022-06-03 | W.L.戈尔及同仁股份有限公司 | Hypotonic blood volume implantable prosthesis with tapered portion |
US9700443B2 (en) | 2015-06-12 | 2017-07-11 | Abbott Cardiovascular Systems Inc. | Methods for attaching a radiopaque marker to a scaffold |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
DE1491218C3 (en) * | 1963-06-15 | 1973-01-04 | Spofa Sdruzheni Podniku Pro Zdravotnickou Vyrobu, Prag | Blood vessel prosthesis and method for making the same |
US3512183A (en) * | 1967-06-08 | 1970-05-19 | Us Health Education & Welfare | Bioelectric polyurethane and use of same in internal prostheses |
US3585647A (en) * | 1968-04-25 | 1971-06-22 | Baxter Laboratories Inc | Antithrombogenic article and process |
US3688317A (en) * | 1970-08-25 | 1972-09-05 | Sutures Inc | Vascular prosthetic |
JPS529074B2 (en) * | 1972-06-22 | 1977-03-14 | ||
AR205110A1 (en) * | 1974-04-02 | 1976-04-05 | Gore & Ass | ARTIFICIAL VASCULAR PROSTHESIS |
US4011861A (en) * | 1974-04-03 | 1977-03-15 | Case Western Reserve University | Implantable electric terminal for organic tissue |
US3914802A (en) * | 1974-05-23 | 1975-10-28 | Ebert Michael | Non-thrombogenic prosthetic material |
US4208745A (en) * | 1976-01-21 | 1980-06-24 | Sumitomo Electric Industries, Ltd. | Vascular prostheses composed of polytetrafluoroethylene and process for their production |
DK139607B (en) * | 1976-04-12 | 1979-03-19 | Biocoating Aps | Biological prosthesis and method of manufacture thereof. |
-
1978
- 1978-10-18 JP JP53128695A patent/JPS6037735B2/en not_active Expired
-
1979
- 1979-10-10 GB GB7935248A patent/GB2033232B/en not_active Expired
- 1979-10-10 IT IT50513/79A patent/IT1128744B/en active
- 1979-10-11 DE DE19792941281 patent/DE2941281A1/en not_active Ceased
- 1979-10-11 AU AU51695/79A patent/AU528494B2/en not_active Expired
- 1979-10-11 BE BE0/197601A patent/BE879356A/en not_active IP Right Cessation
- 1979-10-11 SE SE7908446A patent/SE443288B/en not_active IP Right Cessation
- 1979-10-11 NL NL7907532A patent/NL7907532A/en not_active Application Discontinuation
- 1979-10-12 US US06/084,323 patent/US4321711A/en not_active Expired - Lifetime
- 1979-10-12 FR FR7925494A patent/FR2439005A1/en active Granted
- 1979-10-12 CA CA000337441A patent/CA1140705A/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
BE879356A (en) | 1980-02-01 |
DE2941281A1 (en) | 1980-04-24 |
NL7907532A (en) | 1980-04-22 |
JPS5554951A (en) | 1980-04-22 |
GB2033232A (en) | 1980-05-21 |
JPS6037735B2 (en) | 1985-08-28 |
FR2439005B1 (en) | 1984-11-30 |
AU528494B2 (en) | 1983-04-28 |
SE7908446L (en) | 1980-04-19 |
IT1128744B (en) | 1986-06-04 |
IT7950513A0 (en) | 1979-10-10 |
AU5169579A (en) | 1980-04-24 |
GB2033232B (en) | 1983-03-02 |
US4321711A (en) | 1982-03-30 |
FR2439005A1 (en) | 1980-05-16 |
SE443288B (en) | 1986-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1140705A (en) | Vascular prosthesis | |
CA1140704A (en) | Tubular organic prothesis and process for the production thereof | |
CA1103530A (en) | Composite structure vascular prostheses and process for production thereof | |
US5071609A (en) | Process of manufacturing porous multi-expanded fluoropolymers | |
CA1110402A (en) | Vascular prosthesis having a composite structure and a process for producing same | |
CA1143105A (en) | Tubular organic prosthesis and process for production thereof | |
US20200038550A1 (en) | Porous materials, methods of making and uses | |
JP2020116413A (en) | Porogen compositions, methods of making and uses | |
CA2147565C (en) | Tubular polytetrafluoroethylene implantable prostheses | |
DE69728054T2 (en) | BIORESORABLE SEALING POINTS FOR POROUS ARTIFICIAL VESSELS | |
US5549664A (en) | Artificial blood vessel | |
EP0241838A2 (en) | Antithrombogenic material | |
JPS6341544A (en) | Porous highly expansible fluoropolymers and production thereof | |
CN110548187A (en) | Instant puncture dialysis type nanofiber artificial blood vessel | |
CA1299937C (en) | Antithrombogenic material | |
EP0495127B1 (en) | Artificial blood vessel and production thereof | |
CN211096500U (en) | Instant puncture dialysis type nanofiber artificial blood vessel | |
AU2015215916B2 (en) | Porous materials, methods of making and uses | |
JPS5937979B2 (en) | Composite structure vascular prosthesis and its manufacturing method | |
JPH0622590B2 (en) | Artificial blood vessel and method for producing the same | |
JPS5834137B2 (en) | Composite structure vascular prosthesis and its manufacturing method | |
JP2001346866A (en) | Hybrid resin material and its manufacturing method | |
JPS6244260A (en) | Artificial blood vessel excellent in openability | |
AU724790B2 (en) | Tubular polytetrafluoroethylene implantable prostheses |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |